+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Estudio comparativo entre prazosin y metildopa en hipertensión arterial esencial: resultados de un ensayo terapeutico paralelo, randomizado y doble ciego

      , , , ,


      S. Karger AG

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Se comparó la utilidad de prazosin y metildopa en 16 pacientes con hipertensión esen-cial durante un ensayo randomizado doble ciego y paralelo, que duró seis meses. Ambos fármacos se administraron en combinacion con hidroclorotiazida en dosis de 50 mg, 2 veces al día, hasta que la presión arterial diastólica en decúbito disminuyó a menos de 90 mmHg, o hasta que el paciente recibió prazosin en dosis de 5 mg, 4 veces al día, o metildopa en dosis de 500 mg,4 veces al dia. Al añadir prazosin o metildopa a la hidroclorotiazida, disminuyó la presión arterial significativamente y en grado semejan-te, sin modificar la actividad de renina plasmática. La frecuencia cardiaca y el peso aumentaron de manera significativa durante la administracion de prazosin, pero no con la de metildopa. Los efectos secundarios sintomáticos ocurrieroh con frecuencia igual en el tratamiento con los dos agentes, y no obligaron a modificar ni suspender la terapéutica en algún paciente. La disminución en la frecuencia de administracion de 4 a 2 veces al día o de 3 a 2 veces al dia, hasta 1 vez al día, no tuvo efecto adverse sobre la regulacion de la presión arterial. Al substituir prazosin o metildopa por propranolol se logró eficacia antihipertensiva semejante, con disminución importante de la frecuencia cardiaca.

          Related collections

          Author and article information

          S. Karger AG
          07 November 2008
          : 66
          : Suppl 2
          : 59-67
          División Renal y Laboratorios O’Neill, Departamento de Medicina, Johns Hopkins University School of Medicine y Johns Hopkins Hospital, Baltimore, Maryland, E.U.A.
          173000 Cardiology 1980;66:59–67
          © 1980 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 9
          Prazosin en Hipertensión Arterial I

          General medicine, Neurology, Cardiovascular Medicine, Internal medicine, Nephrology


          Comment on this article